Pcn238 - Time to Approval Using Accelerated Marketing Authorization Pathways: A Study of Five Developed Countries

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.320
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Proposed Study Designs for Approval Based on a Surrogate Endpoint and a Post-Marketing Confirmatory Study Under FDA’s Accelerated Approval Regulations for Disease Modifying Osteoarthritis Drugs

Osteoarthritis and Cartilage
Sports MedicineRheumatologyOrthopedicsBiomedical Engineering
2019English

Php37 - Speeding to Market? An Evaluation of Accelerated Drug Approval Pathways in Australia, Canada, and Saudi Arabia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Php57 - European Conditional Marketing Authorization – Does Early Marketing Authorization Translate Into Early Reimbursement and Patient Access?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

From the FDA: Approval of Medical Devices to Be Accelerated

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1995English

Kyprolis Gains Accelerated Approval for Multiple Myeloma

Cancer Discovery
Oncology
2012English

Economic Crises and Suicides Between 1970 and 2011: Time Trend Study in 21 Developed Countries

Journal of Epidemiology and Community Health
EpidemiologyPublic HealthOccupational HealthEnvironmental
2019English

Socioeconomic Disadvantage and Adolescent Women's Sexual and Reproductive Behavior: The Case of Five Developed Countries

Family Planning Perspectives
2001English

European Welfare Nationalism: A Democratic Forum Study in Five Countries

2018English

Time to Entry for Cancer New Medicines: From European Union–wide Marketing Authorization to Patients Access in Belgium, Estonia, Scotland, and Sweden

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy